Market Place
Sourcing Support
Vivace Therapeutics` VT3989, Shows Strong Antitumor Activity
19 Oct 2025 //
PR NEWSWIRE
Vivace Hits High Note In Midstage Mesothelioma Trial
19 Oct 2025 //
FIERCE BIOTECH
Vivace Therapeutics To Present New Clinical Data at ESMO Congress
09 Oct 2025 //
PR NEWSWIRE
Vivace Therapeutics` VT3989 Granted Fast Track Designation by US
08 Oct 2025 //
PR NEWSWIRE
Vivace Therapeutics Gets Orphan Drug Designation for VT3989
30 Jul 2025 //
PR NEWSWIRE
Researchers Report Clinical Proof-of-Concept Data for Vivace ` VT3989
17 Apr 2023 //
PR NEWSWIRE
Vivace to Unveil First Data for a Cancer Drug Targeting the Hippo Pathway
15 Mar 2023 //
PR NEWSWIRE
Vivace Tx Highlights Strong Synergistic Activity for VT3989 + Osimertinib
11 Apr 2022 //
PRNEWSWIRE
Vivace Therapeutics Announces Issuance of New U.S. Composition of Matter Patents
03 Feb 2022 //
PRNEWSWIRE
Vivace snares $30M to push Hippo-targeting drugs into clinic
16 Dec 2020 //
FIERCEBIOTECH
Vivace Therapeutics scores $30M Series C to take oncology candidate for `Hippo`
16 Dec 2020 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.